Physician profile

Stephen Kushner

Foot & Ankle Surgery · Pembroke Pines, FL

NPI 1184695157

$850.55

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$49.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $271.78 2021-2023 Krystexxa
Stryker Corporation $158.57 2019
Cardiovascular Systems INC. $152.00 2022
Philips North America LLC $108.49 2022
Paratek Pharmaceuticals, INC. $43.69 2022-2023 Nuzyra
Kci USA, INC. $32.43 2019
Smith+Nephew, INC. $31.98 2021
Orthofix Medical, INC. $20.29 2019
Acell, INC. $17.19 2019
Nabriva Therapeutics, Plc $14.13 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen Kushner

$850.55

in general payments reported 2019-2025

Years
2019-2023
Top company
Horizon Therapeutics Plc

https://glasscript.com/doctor/624631/stephen-kushner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.